Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

Tonix Pharmaceuticals (NASDAQ: TNXP) announced that Chief Operating Officer Jessica Morris will present and host investor meetings at NobleCon20, N ...

An intervention program that coaches patients in stress management and goal setting, along with a digital app, helped ...

Dapirolizumab pegol was better than a placebo at controlling disease activity in systemic lupus erythematosus patients in a Phase 3 trial.

CHATHAM, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free ...

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Free Report) – Analysts at Cantor Fitzgerald raised their FY2024 EPS estimates ...

Detailed price information for Eledon Pharmaceuticals Inc (ELDN-Q) from The Globe and Mail including charting and trades.

进入2024年第三季度后，不少大药企研发新一代药物与疗法的步伐加快，希望在未来几年内看见成效。实际上，大范围的专利悬崖正威胁或已蚕食了投资者的预期利润。除了重磅药物失去专利保护外，在一些疾病领域遇阻后，也在刺激制药公司押注新产品。

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...